| Multiple sclerosis progression: time for a new mechanism-driven framework T Kuhlmann, M Moccia, T Coetzee, JA Cohen, J Correale, J Graves, ... The Lancet Neurology 22 (1), 78-88, 2023 | 264 | 2023 |
| Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis S Simpson-Yap, E De Brouwer, T Kalincik, N Rijke, JA Hillert, C Walton, ... Neurology 97 (19), e1870-e1885, 2021 | 240 | 2021 |
| Neurocognitive effects of adjunctive levetiracetam in children with partial‐onset seizures: A randomized, double‐blind, placebo‐controlled, noninferiority trial PM Levisohn, M Mintz, SJ Hunter, H Yang, J Jones, ... Epilepsia 50 (11), 2377-2389, 2009 | 133 | 2009 |
| Axonal loss of retinal neurons in multiple sclerosis associated with optic radiation lesions A Klistorner, P Sriram, N Vootakuru, C Wang, MH Barnett, R Garrick, ... Neurology 82 (24), 2165-2172, 2014 | 126 | 2014 |
| What speech can tell us: A systematic review of dysarthria characteristics in Multiple Sclerosis G Noffs, T Perera, SC Kolbe, CJ Shanahan, FMC Boonstra, A Evans, ... Autoimmunity reviews 17 (12), 1202-1209, 2018 | 107 | 2018 |
| Risk of secondary progressive multiple sclerosis: a longitudinal study A Fambiatos, V Jokubaitis, D Horakova, E Kubala Havrdova, M Trojano, ... Multiple Sclerosis Journal 26 (1), 79-90, 2020 | 90 | 2020 |
| Technologies for advanced gait and balance assessments in people with multiple sclerosis CJ Shanahan, FMC Boonstra, LE Cofré Lizama, M Strik, BA Moffat, ... Frontiers in neurology 8, 708, 2018 | 82 | 2018 |
| A double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremor A Van Der Walt, S Sung, T Spelman, M Marriott, S Kolbe, P Mitchell, ... Neurology 79 (1), 92-99, 2012 | 82 | 2012 |
| Sex effects across the lifespan in women with multiple sclerosis KM Krysko, JS Graves, R Dobson, A Altintas, MP Amato, J Bernard, ... Therapeutic advances in neurological disorders 13, 1756286420936166, 2020 | 81 | 2020 |
| Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination F Tea, JA Lopez, S Ramanathan, V Merheb, FXZ Lee, A Zou, D Pilli, ... Acta Neuropathologica Communications 7, 1-22, 2019 | 81 | 2019 |
| Effect of disease-modifying therapy on disability in relapsing-remitting multiple sclerosis over 15 years T Kalincik, I Diouf, S Sharmin, C Malpas, T Spelman, D Horakova, ... Neurology 96 (5), e783-e797, 2021 | 76 | 2021 |
| Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade A Van der Walt, H Butzkueven, S Kolbe, M Marriott, E Alexandrou, ... Pharmacology & therapeutics 126 (1), 82-93, 2010 | 75 | 2010 |
| Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised … JF Foley, G Defer, LZ Ryerson, JA Cohen, DL Arnold, H Butzkueven, ... The Lancet Neurology 21 (7), 608-619, 2022 | 70 | 2022 |
| Fibre-specific white matter changes in multiple sclerosis patients with optic neuritis S Gajamange, D Raffelt, T Dhollander, E Lui, A van der Walt, T Kilpatrick, ... NeuroImage: Clinical 17, 60-68, 2018 | 70 | 2018 |
| Multiple sclerosis susceptibility-associated SNPs do not influence disease severity measures in a cohort of Australian MS patients CJ Jensen, J Stankovich, A Van der Walt, M Bahlo, BV Taylor, ... PloS one 5 (4), e10003, 2010 | 67 | 2010 |
| COVID-19 in people with multiple sclerosis: a global data sharing initiative LM Peeters, T Parciak, C Walton, L Geys, Y Moreau, E De Brouwer, ... Multiple Sclerosis Journal 26 (10), 1157-1162, 2020 | 63 | 2020 |
| Serum phosphorylated neurofilament-heavy chain levels in multiple sclerosis patients MM Gresle, Y Liu, LF Dagley, J Haartsen, F Pearson, AW Purcell, ... Journal of Neurology, Neurosurgery & Psychiatry 85 (11), 1209-1213, 2014 | 59 | 2014 |
| Optic nerve diffusion tensor imaging after acute optic neuritis predicts axonal and visual outcomes A Van Der Walt, SC Kolbe, YE Wang, A Klistorner, N Shuey, G Ahmadi, ... PLoS One 8 (12), e83825, 2013 | 57 | 2013 |
| Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy A van der Walt, J Stankovich, M Bahlo, BV Taylor, IAF Van der Mei, ... Neurology 73 (13), 1018-1025, 2009 | 57 | 2009 |
| Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: an international consensus statement S Reyes, AL Cunningham, T Kalincik, EK Havrdová, N Isobe, J Pakpoor, ... Journal of neuroimmunology 357, 577627, 2021 | 56 | 2021 |
